GCORE
23.7.2024 08:01:32 CEST | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced it has secured $60 million in Series A funding from institutional and strategic investors. Led by Wargaming, and with participation from Constructor Capital and Han River Partners, this marks the company’s first external capital raise since its inception more than 10 years ago. The funds will be strategically invested in Gcore’s technology and platform, including cutting-edge AI servers powered by NVIDIA GPUs, to drive AI-led innovations. This investment underscores Gcore’s commitment to delivering advanced edge AI solutions that enhance cloud resource efficiency and ensure data sovereignty.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722352056/en/
Gcore, the global edge AI, cloud, network, and security solutions provider (Graphic: Business Wire)
Public organizations, telcos, and global corporations entrust Gcore with their edge workloads due to its expansive network, strong presence in emerging markets, and proven cloud capabilities in AI training and inference. Gcore serves customers across diverse industries, including media and entertainment, gaming, technology, financial services, and retail.
Built for the edge and addressing a $200bn+ market opportunity, Gcore’s cloud infrastructure powers both the training of large language models (LLMs) and the inference of AI applications at the edge. This is enabled by Gcore’s global network of over 180 edge nodes across six continents, including 25+ cloud locations, with a total network capacity exceeding 200 Tbps.
"Gcore has been our partner for over 10 years, helping us deliver games to hundreds of millions of players worldwide. We are excited to support the company on this journey and look forward to helping them become uniquely positioned to lead high-speed AI model training and inference anywhere in the world," said Sean Lee, Chief Corporate Development Officer of Wargaming.
"Constructor Capital is excited to invest in Gcore, a leading player in the AI IaaS space, in a booming market with CAGRs of over 40%. We believe in Gcore’s unique value proposition as a comprehensive provider offering a wide range of edge solutions, high automation, attractive TCO, extremely low latency, and an experienced management team. We look forward to a successful journey together in the years to come," added Matthias Winter, Managing Partner of Constructor Capital.
“We are thrilled to invest in Gcore for its forward-thinking approach to global low-latency AI infrastructure and innovative edge AI solutions,” said Christopher Koh, Managing Partner of HRZ. “We are especially impressed by their leadership in APAC, collaboration with world-class partners, and strategic alignment with emerging AI opportunities in the region.”
“We are on the cusp of an AI revolution that will transform how companies operate,” said Andre Reitenbach, CEO of Gcore. “Gcore is perfectly positioned to connect the world to AI, anywhere and anytime, by delivering innovative AI, cloud, and edge solutions. The growing demand for AI infrastructure from enterprises and SMBs alike highlights the importance of this significant investment. We are thrilled by the support of investors like Wargaming, Constructor Capital, and Han River Partners as we enhance our extensive network of AI servers and reinforce the powerful edge services we offer.”
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, with a team of 600 operating from ten offices worldwide, Gcore provides solutions to global leaders in numerous industries. Gcore manages its global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM due to the average response time of 30 ms worldwide. Gcore’s network consists of 180 points of presence worldwide in reliable Tier IV and Tier III data centers, with a total network capacity exceeding 200 Tbps.
About Wargaming
Wargaming is an award-winning online game developer and publisher headquartered in Nicosia, Cyprus. Operating since 1998, Wargaming has grown to become one of the leaders in the gaming industry with 15 offices around the world, including studios in Chicago, Prague, Shanghai, Tokyo, Vilnius, Kyiv and Guildford. Millions of players enjoy Wargaming's titles across all major gaming platforms. Our flagship products include the free-to-play hits World of Tanks, World of Warships and World of Tanks Blitz.
About Constructor Capital
Constructor Capital is a science-based global Venture Capital fund specializing in investments in early-stage startups within the software and deep technology sectors. The company offers financial investment, mentorship, and strategic support to innovative companies, focusing on scalable products through research and science. Constructor Capital primarily serves sectors such as software technology, deep technology, and education technology.
About Han River Partners
Han River Partners (HRZ) is a globally minded venture investment firm with a focus on the Korea-graph, fundamentally driven by transformative opportunities emerging through disruptive technological innovation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722352056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom